By Fineline Cube 
Quantum Hi-Tech (China) Biotechnology Co., Ltd, known as ChemPartner (SHE: 300149) and Hayoo Biotech have officially entered into a strategic partnership focused on the creation and optimization of novel delivery platforms for small nucleic‑acid drugs. The collaboration targets the burgeoning field of extranodal delivery, seeking to broaden the therapeutic scope of these agents for diseases affecting tissues beyond the bloodstream.
Why This Alliance Matters
- Innovation Gap – Extranodal delivery of nucleic‑acid therapeutics remains a high‑barrier area; the partnership combines ChemPartner’s CRO/CDMO expertise with Hayoo’s proprietary delivery platform.
- Therapeutic Expansion – The joint effort aims to unlock previously untargetable pathogenic gene sequences and enable multi‑payload modulation of several targets simultaneously.
- Strategic Positioning – By jointly advancing a platform that has already shown superior performance in U.S. pre‑clinical studies, both companies position themselves at the forefront of next‑generation gene‑based medicines.
Company Profiles
| Company | Focus | Key Strengths |
|---|---|---|
| ChemPartner | Integrated R&D & manufacturing (CRO/CDMO) | Established track record across drug discovery, pre‑clinical, and GMP manufacturing; headquartered in Shanghai’s Zhangjiang Core Park. |
| Hayoo Biotech | Small‑nucleic‑acid delivery platform | Holds global exclusive licenses to a leading platform technology; core patents enable targeted delivery to pathogenic genes and multi‑payload capacity. |
Technological Highlights
- Targeting Untargetable Sequences – The platform’s unique chemistry allows precise binding to RNA/DNA sequences that were previously inaccessible to therapeutics.
- Multi‑Payload Capability – Enables co‑delivery of siRNA, antisense oligonucleotides, or CRISPR guide RNAs in a single vector, facilitating complex therapeutic regimens.
- Pre‑clinical Validation – U.S. studies demonstrate superior tissue penetration and efficacy in models of glioma, muscular dystrophy, and other extranodal disorders.
Strategic Objectives
- Platform Optimization – Joint R&D to refine delivery vectors for maximal potency and safety in target tissues.
- Pipeline Development – Co‑design early‑stage candidates for diseases such as spinal muscular atrophy, muscular dystrophy, and neuroinflammatory disorders.
- Commercial Pathway – Leverage ChemPartner’s manufacturing capacity to accelerate IND filings and GMP production, while Hayoo supplies the proprietary delivery system.
Market Implications
- Growth Opportunity – The global nucleic‑acid drug market is projected to exceed $20 billion by 2030; extranodal delivery is a high‑growth niche with limited competition.
- Investor Interest – The partnership signals ChemPartner’s expansion beyond traditional CRO services and Hayoo’s commitment to commercialization, likely boosting valuation expectations.
- Regulatory Advantage – Early collaboration with a platform already validated in pre‑clinical settings may streamline regulatory interactions in China and abroad.-Fineline Info & Tech